ArticleIJU case reports2025
Combination of Neoadjuvant Gemcitabine-Cisplatin and Anti-Tuberculosis Therapy for a Patient With Muscle-Invasive Bladder Cancer and Renal Granulomatosis That Progressed After Intravesical Bacillus Calmette-Guérin Therapy.
Article in IJU case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: A case of muscle-invasive bladder cancer and renal granulomatosis that developed after intravesical Bacillus Calmette-Guérin therapy, in which a combination of neoadjuvant gemcitabine-cisplatin and anti-tuberculosis therapy was safely administered, and radical cystectomy was ultimately performed, is reported. Case Presentation: A 64-year-old man with non-muscle-invasive bladder cancer underwent transurethral resection and intravesical Bacillus Calmette-Guérin therapy every time bladder cancer recurred. However, the patient developed left renal granulomatosis during treatment. Anti-tuberculosis therapy was prioritized since there was no bladder cancer progression. However, local bladder cancer progression was observed during the anti-tuberculosis therapy. To successfully cure the renal granulomatosis and suppress tumor progression, neoadjuvant gemcitabine-cisplatin was combined with anti-tuberculosis therapy for 2 months, followed by radical cystectomy. There were no gemcitabine-cisplatin complications and no renal granulomatosis recurrence during combination therapy. Conclusion: Combination of gemcitabine-cisplatin and anti-tuberculosis therapy was possible for a patient with bladder cancer when Bacillus Calmette-Guérin infection was under control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.